Tags

Type your tag names separated by a space and hit enter

Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer's disease.
J Alzheimers Dis 2013; 34(1):171-82JA

Abstract

BACKGROUND

Several studies have reported that peripheral levels of copper and ceruloplasmin (CP) can differentiate patients with Alzheimer's disease (AD) from non-AD cases. The aim of this study was to determine the diagnostic value of serum copper, CP, and non-CP copper levels in a large cohort of AD subjects.

METHODS

Serum copper and CP concentrations were measured at baseline and at 18-months in participants from the Australian Imaging Biomarkers and Lifestyle Study of Ageing. Cross-sectional and longitudinal analyses were conducted using both univariate and multivariate testing adjusting for age, gender, total protein, and ApoE ε4 genotype status.

RESULTS

There was no significant difference in levels of serum copper or CP between the AD and healthy control groups, however, we identified a near-significant decrease in non-CP copper in the mild cognitive impairment and AD groups at baseline (p = 0.02) that was significant at 18-months (p = 0.003).

CONCLUSION

Our results suggest that there may be decreased non-CP copper levels in mild cognitive impairment and AD, which is consistent with diminished copper-dependent biochemical activities described in AD.

Authors+Show Affiliations

The Mental Health Research Institute, The University of Melbourne, VIC, Australia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23168449

Citation

Rembach, Alan, et al. "Longitudinal Analysis of Serum Copper and Ceruloplasmin in Alzheimer's Disease." Journal of Alzheimer's Disease : JAD, vol. 34, no. 1, 2013, pp. 171-82.
Rembach A, Doecke JD, Roberts BR, et al. Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer's disease. J Alzheimers Dis. 2013;34(1):171-82.
Rembach, A., Doecke, J. D., Roberts, B. R., Watt, A. D., Faux, N. G., Volitakis, I., ... Bush, A. I. (2013). Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer's disease. Journal of Alzheimer's Disease : JAD, 34(1), pp. 171-82. doi:10.3233/JAD-121474.
Rembach A, et al. Longitudinal Analysis of Serum Copper and Ceruloplasmin in Alzheimer's Disease. J Alzheimers Dis. 2013;34(1):171-82. PubMed PMID: 23168449.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer's disease. AU - Rembach,Alan, AU - Doecke,James D, AU - Roberts,Blaine R, AU - Watt,Andrew D, AU - Faux,Noel G, AU - Volitakis,Irene, AU - Pertile,Kelly K, AU - Rumble,Rebecca L, AU - Trounson,Brett O, AU - Fowler,Christopher J, AU - Wilson,William, AU - Ellis,Kathryn A, AU - Martins,Ralph N, AU - Rowe,Christopher C, AU - Villemagne,Victor L, AU - Ames,David, AU - Masters,Colin L, AU - AIBL research group,, AU - Bush,Ashley I, PY - 2012/11/22/entrez PY - 2012/11/22/pubmed PY - 2013/9/12/medline SP - 171 EP - 82 JF - Journal of Alzheimer's disease : JAD JO - J. Alzheimers Dis. VL - 34 IS - 1 N2 - BACKGROUND: Several studies have reported that peripheral levels of copper and ceruloplasmin (CP) can differentiate patients with Alzheimer's disease (AD) from non-AD cases. The aim of this study was to determine the diagnostic value of serum copper, CP, and non-CP copper levels in a large cohort of AD subjects. METHODS: Serum copper and CP concentrations were measured at baseline and at 18-months in participants from the Australian Imaging Biomarkers and Lifestyle Study of Ageing. Cross-sectional and longitudinal analyses were conducted using both univariate and multivariate testing adjusting for age, gender, total protein, and ApoE ε4 genotype status. RESULTS: There was no significant difference in levels of serum copper or CP between the AD and healthy control groups, however, we identified a near-significant decrease in non-CP copper in the mild cognitive impairment and AD groups at baseline (p = 0.02) that was significant at 18-months (p = 0.003). CONCLUSION: Our results suggest that there may be decreased non-CP copper levels in mild cognitive impairment and AD, which is consistent with diminished copper-dependent biochemical activities described in AD. SN - 1875-8908 UR - https://www.unboundmedicine.com/medline/citation/23168449/Longitudinal_analysis_of_serum_copper_and_ceruloplasmin_in_Alzheimer's_disease_ L2 - https://content.iospress.com/openurl?genre=article&id=doi:10.3233/JAD-121474 DB - PRIME DP - Unbound Medicine ER -